Table 1 Characteristics of the cohort
C n = 135 | ADNR n = 93 | AR n = 22 | p | ||
|---|---|---|---|---|---|
Recipients | Age (years) | 53.6 ± 12.4 | 50.2 ± 14.2 | 47.8 ± 17.8 | 0.07 |
Sex Ratio (%F) | 34.1 | 39.8 | 45.5 | 0.48 | |
BMI (kg/m2) | 25.1 ± 4.4 | 25.7 ± 5.2 | 24.2 ± 5.6 | 0.35 | |
Dialysis Vintage (days) | 581 [260–777] | 706 [150–1085] | 739 [455–1107] | 0.26 | |
Primary renal disease (%) | 0.02 | ||||
Diabetic nephropathy | 12.6 | 7.5 | 13.6 | ||
Hypertension | 4.4 | 3.2 | 4.6 | ||
Glomerulonephritis/vasculitis | 26.7 | 21.5 | 36.4 | ||
Cystic/hereditary/congenital | 28.2 | 18.3 | 22.7 | ||
Interstitial nephritis/pyelonephritis | 3.7 | 17.2 | 0 | ||
Other/unknown etiology | 24.4 | 32.3 | 22.7 | ||
PRA Max (0–5 /6–84/85–100%) | 80/18.5/1.5 | 75.3/22.6/2.1 | 63.6/22.7/13.6 | 0.13 | |
PRA > 20% (%) | 11.9 | 10.8 | 31.8 | 0.05 | |
Donors | LD (%) | 6.7 | 7.5 | 22.7 | 0.09 |
DCD (%) | 25.4 | 33.7 | 29.4 | 0.42 | |
Age (years) | 43.01 ± 14.5 | 46.8 ± 12 | 47.1 ± 12.9 | 0.08 | |
Sex Ratio (%F) | 45.2 | 51.6 | 50 | 0.62 | |
BMI (kg/m2) | 24.4 ± 4.4 | 25.5 ± 5.2 | 25.4 ± 5.6 | 0.18 | |
Transplantation | Re-transplant (%) | 17.1 | 20.7 | 0 | 0.05 |
CIT (min) | 699 ± 314 | 752 ± 307 | 582 ± 367 | 0.06 | |
HLA MM in toto A + B + DR (n) | 2.7 ± 1.1 | 2.8 ± 1.1 | 3.5 ± 0.9*** | 0.02 | |
Pre-emptive (%) | 8.9 | 18.3 | 13.6 | 0.12 | |
DGF (%) | 14.1 | 26.9 | 22.7 | 0.05 | |
Biopsy | Time (days) | 95 [91–101] | 22 [10–70]*** | 13 [7–43]*** | < 0.01 |
Serum Creatinine Levels (mg/dL) | 1.3 [1.1–1.53] | 2.21 [1.65–3.66]*** | 2.36 [1.72–3.14]*** | < 0.0001 | |
Proteinuria (mg/g creatininuria) | 116 [81–174] | 437 [168–992]*** | 458 [285–1029]*** | < 0.001 | |
CNI (%) | 99.3 | 100 | 100 | 0.54 | |
CsA (%) | 9 | 8.6 | 13.6 | 0.78 | |
MMF derivative (%) | 97 | 97 | 95.5 | 0.93 | |
Oral Steroids (%) | 99.3 | 96.8 | 91 | 0.09 | |
Induction therapy (%) | 0.05 | ||||
Basiliximab | 95.6 | 93.6 | 90.9 | ||
ATG | 2.2 | 3.2 | 0 | ||
None | 1.5 | 0 | 9.1 | ||
Other | 0.7 | 3.2 | 0 |